| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CD223 |
| WB Predicted band size | 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human LAG3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LAG3抗体的3篇代表性文献，按发表时间排序：
---
1. **文献名称**：*Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma*
**作者**：Tawbi, H. A., et al.
**期刊/年份**：*New England Journal of Medicine*, 2022
**摘要**：III期临床试验显示，LAG3抗体Relatlimab联合PD-1抑制剂Nivolumab治疗晚期黑色素瘤，较单用Nivolumab显著延长无进展生存期(中位PFS 10.1 vs 4.6个月)，且安全性可控，支持LAG3作为免疫治疗新靶点。
---
2. **文献名称**：*LAG3 (CD223) as a cancer immunotherapy target*
**作者**：Andrews, L. P., et al.
**期刊/年份**：*Cancer Discovery*, 2018
**摘要**：综述LAG3的生物学功能，揭示其通过结合MHC II类分子抑制T细胞活性，并与PD-1协同促进肿瘤免疫逃逸。临床前数据支持LAG3抗体联合PD-1/PD-L1抑制剂增强抗肿瘤效果。
---
3. **文献名称**：*LAG3 limits regulatory T cell persistence in the tumor microenvironment*
**作者**：Huang, C. T., et al.
**期刊/年份**：*Journal of Clinical Investigation*, 2017
**摘要**：机制研究显示，LAG3在肿瘤微环境中通过调控Treg细胞功能促进免疫抑制。阻断LAG3可减少Treg浸润并增强效应T细胞的抗肿瘤反应，为联合治疗提供理论依据。
---
**扩展建议**：若需更多文献，可关注2023年LAG3抗体在非小细胞肺癌(NSCLC)或淋巴瘤中的研究进展。
LAG3 (Lymphocyte-Activation Gene 3), a cell surface protein belonging to the immunoglobulin superfamily, functions as an immune checkpoint receptor that negatively regulates T-cell activation and homeostasis. Primarily expressed on activated T cells, regulatory T cells (Tregs), and natural killer (NK) cells, LAG3 interacts with MHC class II molecules and other ligands, such as fibrinogen-like protein 1 (FGL1), to suppress effector T-cell proliferation, cytokine secretion, and cytotoxicity. This inhibitory mechanism helps maintain immune tolerance but is often exploited by tumors to evade immune surveillance.
Research over the past decade has highlighted LAG3 as a promising therapeutic target, particularly in combination with other checkpoint inhibitors like PD-1/PD-L1 blockers. Preclinical studies demonstrated that LAG3 blockade rejuvenates exhausted T cells and synergizes with anti-PD-1 therapies to enhance antitumor responses. In 2022. the FDA approved relatlimab (a LAG3 inhibitor) combined with nivolumab (anti-PD-1) for advanced melanoma, marking the first LAG3-targeted therapy to reach clinical use.
Ongoing trials explore LAG3 antibodies in diverse cancers, including lymphoma, lung, and colorectal cancer. Challenges remain in optimizing dosing, understanding resistance mechanisms, and identifying predictive biomarkers. Despite these hurdles, LAG3 inhibition represents a critical advancement in cancer immunotherapy, expanding treatment options beyond traditional checkpoint targets.
×
